A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushings disease
A study for patients with Cushing's disease using study drug LCI699
Sponsor: Novartis Pharmaceuticals Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN9602
U.S. Govt. ID: NCT02180217
Contact: Santo Fernandez: 212-305-4921 / sjf2132@columbia.edu
Additional Study Information: The purpose of this study is to confirm the effectiveness and safety of LCI699 in treating patients with Cushing's disease. Patients will be treated with the invesitigational drug LCI699 at doses up to 60 mg a day, and possibly for a short period of time with placebo. A placebo is a dummy drug ("pill") with no active medicine inside.
This study is closed
Investigator
Pamela Freda, MD
Do You Qualify?
Do you have a confirmed diagnosis of Cushing's disease? Yes No
Are you currently taking any investigational drugs? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Santo Fernandez
sjf2132@columbia.edu
212-305-4921
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE